NCT03411473View on ClinicalTrials.gov

Study of AGEN1884 With Pembrolizumab in 1L NSCLC

PHASE2TerminatedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

October 4, 2017

Primary Completion Date

May 1, 2018

Study Completion Date

March 1, 2019

Conditions
NSCLC Stage IV
Interventions
BIOLOGICAL

AGEN1884 in combination with pembrolizumab

AGEN1884 in combination with pembrolizumab in subjects with stage IV NSCLC whose tumors have high PD-L1 expression and no EGFR or ALK genomic tumor aberrations

Trial Locations (5)

Unknown

Mater Research, Brisbane

Scientia Clinical Research, Sydney

John Flynn Private Hospital, Tugun

Sydney Adventist, Wahroonga

Auckland City Hospital, Auckland

Sponsors

Lead Sponsor

Agenus Inc.
All Listed Sponsors
lead

Agenus Inc.

INDUSTRY

NCT03411473 - Study of AGEN1884 With Pembrolizumab in 1L NSCLC | Biotech Hunter | Biotech Hunter